JPWO2019210828A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019210828A5 JPWO2019210828A5 JP2020555218A JP2020555218A JPWO2019210828A5 JP WO2019210828 A5 JPWO2019210828 A5 JP WO2019210828A5 JP 2020555218 A JP2020555218 A JP 2020555218A JP 2020555218 A JP2020555218 A JP 2020555218A JP WO2019210828 A5 JPWO2019210828 A5 JP WO2019210828A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- tetrahydro
- sulfonyl
- oxy
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 -cycloalkyl Chemical group 0.000 claims 404
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 322
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 193
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 108
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 103
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 80
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 78
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 74
- 125000000623 heterocyclic group Chemical group 0.000 claims 46
- 125000000217 alkyl group Chemical group 0.000 claims 40
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims 39
- 150000001875 compounds Chemical class 0.000 claims 34
- 125000001072 heteroaryl group Chemical group 0.000 claims 28
- 125000003118 aryl group Chemical group 0.000 claims 27
- 125000000304 alkynyl group Chemical group 0.000 claims 26
- 125000000753 cycloalkyl group Chemical group 0.000 claims 25
- 229910052739 hydrogen Inorganic materials 0.000 claims 25
- 239000001257 hydrogen Substances 0.000 claims 25
- 125000003342 alkenyl group Chemical group 0.000 claims 24
- 229910052736 halogen Inorganic materials 0.000 claims 17
- 150000002367 halogens Chemical group 0.000 claims 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 16
- 125000004043 oxo group Chemical group O=* 0.000 claims 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 13
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 12
- 229910052760 oxygen Inorganic materials 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 12
- 229910052757 nitrogen Inorganic materials 0.000 claims 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 10
- 239000001301 oxygen Substances 0.000 claims 10
- 150000002431 hydrogen Chemical group 0.000 claims 9
- 125000002950 monocyclic group Chemical group 0.000 claims 9
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- KZKRRZFCAYOXQE-UHFFFAOYSA-N 1$l^{2}-azinane Chemical group C1CC[N]CC1 KZKRRZFCAYOXQE-UHFFFAOYSA-N 0.000 claims 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 7
- 235000010290 biphenyl Nutrition 0.000 claims 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000011593 sulfur Substances 0.000 claims 3
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims 2
- AGJDXCXJDWGXSZ-UHFFFAOYSA-N 1-(azetidin-3-yl)-2-(2-cyclopropylphenyl)pyrrolidine Chemical compound N1CC(C1)N1C(CCC1)C1=C(C=CC=C1)C1CC1 AGJDXCXJDWGXSZ-UHFFFAOYSA-N 0.000 claims 2
- VLSBQVKHSCWDRV-UHFFFAOYSA-N 4-fluoro-1-(oxetan-3-yl)piperidine Chemical compound FC1CCN(CC1)C1COC1 VLSBQVKHSCWDRV-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 230000001640 apoptogenic effect Effects 0.000 claims 2
- 125000005605 benzo group Chemical group 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- GUOAGGANPURUME-UHFFFAOYSA-N 1,4,5,6-tetrahydropyrrolo[3,2-c]pyrazole Chemical compound N1N=CC2=C1CCN2 GUOAGGANPURUME-UHFFFAOYSA-N 0.000 claims 1
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims 1
- KKBIAIYZUNQLQH-UHFFFAOYSA-N 1-methylsulfonyl-3,6-dihydro-2h-pyridine Chemical compound CS(=O)(=O)N1CCC=CC1 KKBIAIYZUNQLQH-UHFFFAOYSA-N 0.000 claims 1
- RQTXIRLKGQYDFE-UHFFFAOYSA-N 3-(dimethylamino)-1-piperidin-1-ylpropan-1-one Chemical compound CN(C)CCC(=O)N1CCCCC1 RQTXIRLKGQYDFE-UHFFFAOYSA-N 0.000 claims 1
- AERFXRCBKUZMBQ-UHFFFAOYSA-N 4-[4-(3,3-dimethyl-2-oxo-5-phenylpyrrolidin-1-yl)phenyl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C1=C(C2N(C(=O)C(C)(C)C2)C2=CC=C(C3=CC(OC4=CN=C5NC=CC5=C4)=C(C(=O)NS(=O)(=O)C4=CC=C(NCC5CCOCC5)C(=C4)N(=O)=O)C=C3)C=C2)C=CC=C1 AERFXRCBKUZMBQ-UHFFFAOYSA-N 0.000 claims 1
- LUQVCHRDAGWYMG-UHFFFAOYSA-N 4-phenylbenzamide Chemical compound C1=CC(C(=O)N)=CC=C1C1=CC=CC=C1 LUQVCHRDAGWYMG-UHFFFAOYSA-N 0.000 claims 1
- OFNWMZRPXFBZPX-UHFFFAOYSA-N 8-methyl-3,8-diazabicyclo[3.2.1]octane Chemical compound C1NCC2CCC1N2C OFNWMZRPXFBZPX-UHFFFAOYSA-N 0.000 claims 1
- RBFKRQHNIKFHRC-UHFFFAOYSA-N N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-4-[4-[2-(2-phenylphenyl)pyrrolidin-1-yl]phenyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C=1(C=CC=CC=1)C1=C(C2CCCN2C2=CC=C(C3=CC(OC4=CN=C5C(=C4)C=CN5)=C(C(=O)NS(=O)(=O)C4=CC(N(=O)=O)=C(NCC5CCOCC5)C=C4)C=C3)C=C2)C=CC=C1 RBFKRQHNIKFHRC-UHFFFAOYSA-N 0.000 claims 1
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 150000001345 alkine derivatives Chemical class 0.000 claims 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 claims 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- 125000005322 morpholin-1-yl group Chemical group 0.000 claims 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 claims 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 claims 1
- ZKWFSTHEYLJLEL-UHFFFAOYSA-N morpholine-4-carboxamide Chemical compound NC(=O)N1CCOCC1 ZKWFSTHEYLJLEL-UHFFFAOYSA-N 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 125000006501 nitrophenyl group Chemical group 0.000 claims 1
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 claims 1
- 125000004574 piperidin-2-yl group Chemical group N1C(CCCC1)* 0.000 claims 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- XMVJITFPVVRMHC-UHFFFAOYSA-N roxarsone Chemical group OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004187 tetrahydropyran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024094048A JP7540113B1 (ja) | 2018-04-29 | 2024-06-11 | Ｂｃｌ－２阻害剤 |
| JP2024135320A JP7688210B2 (ja) | 2018-04-29 | 2024-08-14 | Ｂｃｌ－２阻害剤 |
| JP2025085498A JP2025119001A (ja) | 2018-04-29 | 2025-05-22 | Ｂｃｌ－２阻害剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018085217 | 2018-04-29 | ||
| CNPCT/CN2018/085217 | 2018-04-29 | ||
| CNPCT/CN2018/107134 | 2018-09-21 | ||
| CN2018107134 | 2018-09-21 | ||
| PCT/CN2019/085001 WO2019210828A1 (en) | 2018-04-29 | 2019-04-29 | Bcl-2 INHIBITORS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024094048A Division JP7540113B1 (ja) | 2018-04-29 | 2024-06-11 | Ｂｃｌ－２阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021521138A JP2021521138A (ja) | 2021-08-26 |
| JPWO2019210828A5 true JPWO2019210828A5 (enExample) | 2022-04-22 |
Family
ID=68386968
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555218A Withdrawn JP2021521138A (ja) | 2018-04-29 | 2019-04-29 | Ｂｃｌ−２阻害剤 |
| JP2024094048A Active JP7540113B1 (ja) | 2018-04-29 | 2024-06-11 | Ｂｃｌ－２阻害剤 |
| JP2024135320A Active JP7688210B2 (ja) | 2018-04-29 | 2024-08-14 | Ｂｃｌ－２阻害剤 |
| JP2025085498A Pending JP2025119001A (ja) | 2018-04-29 | 2025-05-22 | Ｂｃｌ－２阻害剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024094048A Active JP7540113B1 (ja) | 2018-04-29 | 2024-06-11 | Ｂｃｌ－２阻害剤 |
| JP2024135320A Active JP7688210B2 (ja) | 2018-04-29 | 2024-08-14 | Ｂｃｌ－２阻害剤 |
| JP2025085498A Pending JP2025119001A (ja) | 2018-04-29 | 2025-05-22 | Ｂｃｌ－２阻害剤 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US11420968B2 (enExample) |
| EP (2) | EP3788042B1 (enExample) |
| JP (4) | JP2021521138A (enExample) |
| KR (1) | KR102738032B1 (enExample) |
| CN (3) | CN112437772B (enExample) |
| AU (1) | AU2019264475C1 (enExample) |
| BR (1) | BR112020022092A2 (enExample) |
| CA (1) | CA3098348A1 (enExample) |
| DK (1) | DK3788042T3 (enExample) |
| ES (1) | ES3018793T3 (enExample) |
| FI (1) | FI3788042T3 (enExample) |
| HR (1) | HRP20250392T1 (enExample) |
| HU (1) | HUE071493T2 (enExample) |
| IL (1) | IL278366B2 (enExample) |
| LT (1) | LT3788042T (enExample) |
| MX (2) | MX2020011495A (enExample) |
| PL (1) | PL3788042T3 (enExample) |
| PT (1) | PT3788042T (enExample) |
| SG (1) | SG11202009933WA (enExample) |
| SI (1) | SI3788042T1 (enExample) |
| TW (1) | TWI855062B (enExample) |
| WO (1) | WO2019210828A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3565815B1 (en) | 2017-01-07 | 2024-03-13 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2-selective apoptosis-inducing agents |
| HUE060310T2 (hu) | 2017-04-18 | 2023-02-28 | Shanghai Fochon Pharmaceutical Co Ltd | Apoptosis-indukáló szerek |
| CA3087262A1 (en) | 2018-01-10 | 2019-07-18 | Recurium Ip Holdings, Llc | Benzamide compounds |
| MX2020011495A (es) | 2018-04-29 | 2021-01-15 | Beigene Ltd | Inhibidores de bcl-2. |
| WO2020140005A2 (en) | 2018-12-29 | 2020-07-02 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| WO2021083135A1 (en) * | 2019-10-28 | 2021-05-06 | Beigene, Ltd. | Bcl-2 INHIBITORS |
| WO2021110102A1 (en) * | 2019-12-02 | 2021-06-10 | Beigene, Ltd. | Methods of cancer treatment using bcl-2 inhibitor |
| MX2022006631A (es) | 2019-12-06 | 2022-09-07 | Loxo Oncology Inc | Dosificacion de un inhibidor de la tirosina cinasa de bruton. |
| WO2021133817A1 (en) | 2019-12-27 | 2021-07-01 | Guangzhou Lupeng Pharmaceutical Company Ltd. | 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| KR20230002419A (ko) * | 2020-04-15 | 2023-01-05 | 베이진 엘티디 | Bcl-2 억제제 |
| US20230159527A1 (en) * | 2020-05-08 | 2023-05-25 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2 inhibitors |
| WO2022089463A1 (zh) * | 2020-10-28 | 2022-05-05 | 杭州和正医药有限公司 | Bcl-2蛋白凋亡诱导剂及应用 |
| AU2022240765A1 (en) * | 2021-03-19 | 2023-09-07 | Eil Therapeutics, Inc. | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as bcl-2 inhibitors |
| WO2022218311A1 (en) * | 2021-04-13 | 2022-10-20 | Appicine Therapeutics (Hk) Limited | Modulators of bcl-2 or bcl-2/bcl-xl and uses thereof |
| PH12023553203A1 (en) * | 2021-06-02 | 2024-02-19 | Beigene Switzerland Gmbh | Methods of treating b-cell malignancy using bcl-2 inhibitor |
| CN115490708B (zh) * | 2021-06-18 | 2025-01-24 | 苏州亚盛药业有限公司 | 磺酰胺类大环衍生物及其制备方法和用途 |
| IL311106A (en) * | 2021-08-31 | 2024-04-01 | Beigene Ltd | Solid forms of BCL-2 inhibitors, their method of preparation and use |
| WO2023078398A1 (en) * | 2021-11-05 | 2023-05-11 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2 inhibitors |
| US20250122191A1 (en) * | 2021-11-20 | 2025-04-17 | Fochon Biosciences, Ltd | Compounds as bcl-2 inhibitors |
| WO2023104043A1 (zh) | 2021-12-06 | 2023-06-15 | 杭州和正医药有限公司 | 一种抗凋亡蛋白bcl-2抑制剂、药物组合物及其应用 |
| TW202400163A (zh) | 2022-05-12 | 2024-01-01 | 英屬開曼群島商百濟神州有限公司 | 使用ｂｃｌ－２抑制劑治療髓性惡性腫瘤之方法 |
| WO2023231777A1 (en) * | 2022-06-01 | 2023-12-07 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2 inhibitors |
| WO2024017354A1 (en) * | 2022-07-21 | 2024-01-25 | Beigene, Ltd. | Methods of treating multiple myeloma using bcl-2 inhibitor |
| WO2024140692A1 (en) * | 2022-12-27 | 2024-07-04 | Beigene (Suzhou) Co., Ltd. | Salts and solid forms of sonrotoclax intermediate |
| JP2026503231A (ja) * | 2022-12-27 | 2026-01-28 | ビーワン メディシンズ ワン ゲーエムベーハー | Ｓｏｎｒｏｔｏｃｌａｘの中間体及びその調製方法 |
| EP4642781A1 (en) * | 2022-12-27 | 2025-11-05 | Beone Medicines I GmbH | A ketal protected intermediate for sonrotoclax and preparation method thereof |
| WO2026002056A1 (en) | 2024-06-26 | 2026-01-02 | Beone Pharmaceutical (Suzhou) Co., Ltd. | A pharmaceutical formulation comprising solid dispersion of sonrotoclax and a process of preparation thereof |
| WO2026019442A1 (en) * | 2024-07-14 | 2026-01-22 | Eil Therapeutics, Inc. | Compounds having (3-nitrophenyl)acetamide as bcl-2 inhibitors |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY26942A1 (es) * | 2000-09-20 | 2002-04-26 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| US20020055631A1 (en) | 2000-09-20 | 2002-05-09 | Augeri David J. | N-acylsulfonamide apoptosis promoters |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| CA2577752A1 (en) | 2004-08-20 | 2006-03-02 | The Regents Of The University Of Michigan | Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof |
| PT1888550E (pt) | 2005-05-12 | 2014-09-03 | Abbvie Bahamas Ltd | Promotores de apoptose |
| JP5147688B2 (ja) | 2005-05-24 | 2013-02-20 | アボット・ラボラトリーズ | アポトーシス促進剤 |
| EP2061560A2 (en) | 2006-09-05 | 2009-05-27 | Abbott Laboratories | Bcl inhibitors for treating platelet excess |
| WO2009036051A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Bcl-2 inhibitors containing a zinc binding moiety |
| JP5415530B2 (ja) | 2008-06-09 | 2014-02-12 | ブリストル−マイヤーズ スクイブ カンパニー | 抗アポトーシスＢｃｌ阻害剤としてのヒドロキシフェニルスルホンアミド |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| UA108193C2 (uk) | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| NZ592801A (en) | 2008-12-05 | 2013-08-30 | Abbvie Inc | Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| MX2011006000A (es) | 2008-12-08 | 2011-07-20 | Boehringer Ingelheim Int | Compuestos para tratar cancer. |
| CN102282128B (zh) | 2009-01-19 | 2015-06-17 | Abbvie公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
| HUE025527T2 (en) | 2009-01-19 | 2016-04-28 | Abbvie Inc | Apoptosis inducers for the treatment of cancer, immune and autoimmune diseases |
| US8546399B2 (en) * | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CN102448959B (zh) | 2009-05-26 | 2015-06-17 | 艾伯维巴哈马有限公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
| MX2012003007A (es) | 2009-09-10 | 2012-04-11 | Novartis Ag | Sulfonamidas como inhibidores de las proteinas de la familia bcl-2 para el tratamiento de cancer. |
| RU2568611C2 (ru) | 2010-03-25 | 2015-11-20 | Эббви Инк. | Средства, индуцирующие апоптоз, для лечения рака, иммунных и аутоиммунных заболеваний |
| TWI520960B (zh) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
| TWI535712B (zh) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
| CA2811805A1 (en) | 2010-10-29 | 2012-05-03 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
| IT1403156B1 (it) | 2010-12-01 | 2013-10-04 | Università Degli Studi Di Torino | Inibitori di fosfatidilinositol 3-chinasi, relative composizioni ed usi. |
| US8691184B2 (en) | 2011-01-25 | 2014-04-08 | The Regents Of The University Of Michigan | Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same |
| US9346795B2 (en) | 2011-05-25 | 2016-05-24 | Bristol-Myers Squibb Company | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors |
| WO2013053045A1 (en) | 2011-10-12 | 2013-04-18 | Beta Pharma Canada Inc. | Heterocyclic molecules as apoptosis inducers |
| BR112014015322A8 (pt) | 2011-12-23 | 2017-06-13 | Novartis Ag | compostos e composições para inibir a interação de bcl2 com parceiros de ligação |
| WO2013096055A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
| CA2859873A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
| CN104125955A (zh) | 2011-12-23 | 2014-10-29 | 诺华股份有限公司 | 用于抑制bcl2与结合配偶体相互作用的化合物 |
| MX2014007731A (es) | 2011-12-23 | 2015-01-12 | Novartis Ag | Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace. |
| WO2013185202A1 (en) | 2012-06-14 | 2013-12-19 | Beta Pharma Canada Inc | Apoptosis inducers |
| KR102318204B1 (ko) | 2013-01-16 | 2021-10-26 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | Bcl-2bcl-xl 억제제 및 그를 사용하는 치료 방법 |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| WO2017132474A1 (en) | 2016-01-30 | 2017-08-03 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| EP3481397A1 (en) | 2016-07-06 | 2019-05-15 | Concert Pharmaceuticals Inc. | Deuterated venetoclax |
| CN110483501B (zh) | 2016-08-05 | 2022-07-01 | 密歇根大学董事会 | 作为bcl-2抑制剂的n-(苯基磺酰基)苯甲酰胺及相关化合物 |
| CN109641897B (zh) | 2016-09-01 | 2021-12-07 | 北京赛林泰医药技术有限公司 | Bcl-2选择性抑制剂及其制备和用途 |
| CN106565706B (zh) | 2016-10-27 | 2018-05-01 | 广东东阳光药业有限公司 | 一种磺酰胺衍生物及其在药学中的应用 |
| CN106749233B (zh) | 2016-11-24 | 2020-04-21 | 中山大学 | 一类磺酰胺衍生物及其应用 |
| EP3565815B1 (en) | 2017-01-07 | 2024-03-13 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2-selective apoptosis-inducing agents |
| HUE060310T2 (hu) | 2017-04-18 | 2023-02-28 | Shanghai Fochon Pharmaceutical Co Ltd | Apoptosis-indukáló szerek |
| MX2020002033A (es) | 2017-08-23 | 2020-08-20 | Guangzhou Lupeng Pharmaceutical Company Ltd | Derivados heterociclicos condensados como inhibidores de bcl-2 para el tratamiento de enfermedades neoplasticas. |
| MX2020011495A (es) * | 2018-04-29 | 2021-01-15 | Beigene Ltd | Inhibidores de bcl-2. |
| WO2020140005A2 (en) | 2018-12-29 | 2020-07-02 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| WO2021083135A1 (en) | 2019-10-28 | 2021-05-06 | Beigene, Ltd. | Bcl-2 INHIBITORS |
| WO2021110102A1 (en) | 2019-12-02 | 2021-06-10 | Beigene, Ltd. | Methods of cancer treatment using bcl-2 inhibitor |
-
2019
- 2019-04-29 MX MX2020011495A patent/MX2020011495A/es unknown
- 2019-04-29 ES ES19797052T patent/ES3018793T3/es active Active
- 2019-04-29 WO PCT/CN2019/085001 patent/WO2019210828A1/en not_active Ceased
- 2019-04-29 KR KR1020207033817A patent/KR102738032B1/ko active Active
- 2019-04-29 DK DK19797052.8T patent/DK3788042T3/da active
- 2019-04-29 CN CN201980029015.1A patent/CN112437772B/zh active Active
- 2019-04-29 PL PL19797052.8T patent/PL3788042T3/pl unknown
- 2019-04-29 LT LTEPPCT/CN2019/085001T patent/LT3788042T/lt unknown
- 2019-04-29 HR HRP20250392TT patent/HRP20250392T1/hr unknown
- 2019-04-29 SI SI201930922T patent/SI3788042T1/sl unknown
- 2019-04-29 EP EP19797052.8A patent/EP3788042B1/en active Active
- 2019-04-29 PT PT197970528T patent/PT3788042T/pt unknown
- 2019-04-29 CA CA3098348A patent/CA3098348A1/en active Pending
- 2019-04-29 AU AU2019264475A patent/AU2019264475C1/en active Active
- 2019-04-29 BR BR112020022092-2A patent/BR112020022092A2/pt unknown
- 2019-04-29 JP JP2020555218A patent/JP2021521138A/ja not_active Withdrawn
- 2019-04-29 SG SG11202009933WA patent/SG11202009933WA/en unknown
- 2019-04-29 IL IL278366A patent/IL278366B2/en unknown
- 2019-04-29 CN CN202311185016.XA patent/CN117430601A/zh active Pending
- 2019-04-29 US US17/050,581 patent/US11420968B2/en active Active
- 2019-04-29 EP EP25150254.8A patent/EP4545515A1/en active Pending
- 2019-04-29 FI FIEP19797052.8T patent/FI3788042T3/fi active
- 2019-04-29 CN CN202311486964.7A patent/CN117683029A/zh active Pending
- 2019-04-29 HU HUE19797052A patent/HUE071493T2/hu unknown
-
2020
- 2020-04-28 TW TW109114185A patent/TWI855062B/zh active
- 2020-10-29 MX MX2023001689A patent/MX2023001689A/es unknown
-
2022
- 2022-05-23 US US17/750,821 patent/US12077536B2/en active Active
-
2024
- 2024-06-11 JP JP2024094048A patent/JP7540113B1/ja active Active
- 2024-06-17 US US18/745,423 patent/US20240376104A1/en active Pending
- 2024-08-14 JP JP2024135320A patent/JP7688210B2/ja active Active
-
2025
- 2025-05-22 JP JP2025085498A patent/JP2025119001A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019210828A5 (enExample) | ||
| IL278366B2 (en) | BCL-2 inhibitors | |
| US11718602B2 (en) | EGFR inhibitors | |
| JP2018530557A5 (enExample) | ||
| JP2023166614A (ja) | Ｓｈｐ２ホスファターゼ阻害剤およびこれらの使用方法 | |
| ES2548532T3 (es) | Compuestos de pirrolopirimidina como inhibidores de CDK4/6 | |
| AR119209A1 (es) | DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR | |
| JP2014506929A5 (enExample) | ||
| RU2020129785A (ru) | Фармацевтические производные 6,5-гетеробициклического кольца | |
| JP2007536252A5 (enExample) | ||
| RU2018126774A (ru) | Ингибиторы менин-mll взаимодействия | |
| JPWO2023018812A5 (enExample) | ||
| IL277579B (en) | Piperidinone derivatives as mdm2 inhibitors for cancer therapy | |
| JP2015524798A5 (enExample) | ||
| JP2018503674A5 (enExample) | ||
| JP2015522002A5 (enExample) | ||
| RU2016135637A (ru) | 6-гетероарилокси- и 6-арилоксихинолин-2-карбоксамиды и их применение | |
| TW201735769A (zh) | 經取代之吡唑并［３，４－ｂ］吡啶－６－羧酸及使用方法 | |
| JP2019530725A5 (enExample) | ||
| JP2015513552A5 (enExample) | ||
| RU2017117248A (ru) | Этил-n-boc-пиперидинил-пиразоло-пиридоны в качестве ингибиторов янус-киназы | |
| HRP20210285T1 (hr) | Derivati ((piridin-2-il)-amino)pirido[3,4-d]pirimidina i ((piridazin-3-il)-amino)pirido[3,4-d]pirimidina kao inhibitori cdk4/6 za liječenje npr. reumatoidnog artritisa, arterioskleroze, plućne fibroze, cerebralnog infarkta ili raka | |
| RU2008147542A (ru) | Агонисты мускариновых рецепторов, эффективные при лечении боли, болезни альцгеймера и шизофрении | |
| AU2018377993A1 (en) | Pyrazolopyrimidines having activity against the respiratory syncytial virus (rsv) | |
| JPWO2022216573A5 (enExample) |